{
    "clinical_study": {
        "@rank": "156594", 
        "arm_group": [
            {
                "arm_group_label": "Evacetrapib Single", 
                "arm_group_type": "Experimental", 
                "description": "Part 1, Cohort A, Period 1, Participants will receive a single oral 130 mg dose of evacetrapib."
            }, 
            {
                "arm_group_label": "Evacetrapib Multiple", 
                "arm_group_type": "Experimental", 
                "description": "Part 1, Cohort A, Period 2, Participants will receive multiple doses of evacetrapib for 14 days."
            }, 
            {
                "arm_group_label": "Simvastatin", 
                "arm_group_type": "Active Comparator", 
                "description": "Part 2, Cohorts B, Participants will receive simvastatin orally, once daily on Days 1 - 4."
            }, 
            {
                "arm_group_label": "Evacetrapib and Simvastatin", 
                "arm_group_type": "Experimental", 
                "description": "Part 2, Cohorts B, Participants will receive evacetrapib orally once daily on Days 5 - 14 and simvastatin orally, once daily on Days 15 - 22."
            }, 
            {
                "arm_group_label": "Atorvastatin", 
                "arm_group_type": "Active Comparator", 
                "description": "Part 2, Cohorts C, Participants will receive atorvastatin orally, once daily on Days 1 - 4."
            }, 
            {
                "arm_group_label": "Evacetrapib and Atorvastatin", 
                "arm_group_type": "Experimental", 
                "description": "Part 2, Cohorts C, Participants will receive evacetrapib orally once daily on Days 5 - 14 and atorvastatin orally, once daily on Days 15 - 22."
            }
        ], 
        "brief_summary": {
            "textblock": "The main purpose of this study is to investigate how the body responds to evacetrapib and to\n      evaluate the safety and the effect of evacetrapib, alone and in combination with selected\n      statins, in healthy Chinese participants. The study has 2 parts.  Part one will last up to 4\n      weeks and part two will last up to 5 weeks, not including screening.  Participants may only\n      enroll in one part."
        }, 
        "brief_title": "A Study of Evacetrapib With Selected Statins in Healthy Chinese Participants", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Are native Chinese and living in China.\n\n          -  Are overtly healthy males or females as determined by medical history and physical\n             examination.\n\n          -  Female participants:\n\n               -  Women not of child-bearing potential\n\n               -  Women of child-bearing potential must correctly use 2 forms of reliable\n                  contraception to avoid getting pregnant during the study and for 3 months after\n                  the study is completed.\n\n          -  Body Mass Index: 19.0 to 24.0 kilogram per square meter (kg/m^2)\n\n          -  BP and pulse rate at both supine and standing positions of approximately a systolic\n             BP \u2264 140 milimeter of mercury (mm Hg), and diastolic BP \u2264 90 mm Hg\n\n          -  Participants with untreated hypercholesterolemia may be included if not on an herbal\n             or other traditional Chinese medicines (TCM)\n\n          -  Have no known liver disease\n\n          -  Have given written informed consent\n\n        Exclusion Criteria:\n\n          -  Are currently enrolled in a clinical trial involving an investigational product (IP)\n             or off-label use of a drug or device, or are concurrently enrolled in any other type\n             of medical research judged not to be scientifically or medically compatible with this\n             study.\n\n          -  Have known allergies to evacetrapib, simvastatin, or atorvastatin, related compounds\n             or any components of the formulation\n\n          -  Have previously completed or withdrawn from this study or any other study\n             investigating evacetrapib, and have previously received the IP within 3 months.\n\n          -  Have a history within the last year or presence of cardiovascular, respiratory,\n             hepatic, renal, gastrointestinal, endocrine, hematologic, or neurologic disorders\n             capable of significantly altering the absorption, metabolism, or elimination of\n             drugs; of constituting a risk when taking the study medication; or of interfering\n             with the interpretation of data.\n\n          -  Show evidence of significant active neuropsychiatric disease.\n\n          -  Regularly use known drugs of abuse\n\n          -  Are women with a positive pregnancy test or women who are lactating.\n\n          -  Have used or intend to use over-the-counter or prescription medications (including\n             vitamins/mineral supplements) or TCM 14 days prior to the first dose and during the\n             study.\n\n               -  Hormonal contraceptives are permitted.\n\n          -  Use of any drugs or substances that are known to be substrates, inducers, or\n             inhibitors of organic anion transporting polypeptide 1B1 (OATP1B1), or of any other\n             transporters involved in simvastatin or atorvastatin disposition, or of any drugs or\n             substances that are known to be strong inducers or inhibitors of cytochrome P450 3A\n             (CYP3A) within 30 days prior to the first dose and throughout the study.\n\n          -  Donated blood of >400 mL within the last month.\n\n          -  Drink alcoholic beverages with intake that exceeds 28 units per week (males) and 21\n             units per week (females), or are unwilling to stop alcohol consumption 48 hours prior\n             to dosing until discharge from the clinical research unit (CRU) (1 unit = 12 oz or\n             360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits).\n\n          -  Are unwilling to comply with the dietary requirements/restrictions during the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "66", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02156492", 
            "org_study_id": "14467", 
            "secondary_id": "I1V-MC-EIAM"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Evacetrapib Single", 
                    "Evacetrapib Multiple", 
                    "Evacetrapib and Simvastatin", 
                    "Evacetrapib and Atorvastatin"
                ], 
                "description": "Administered orally.", 
                "intervention_name": "Evacetrapib", 
                "intervention_type": "Drug", 
                "other_name": "LY2484595"
            }, 
            {
                "arm_group_label": [
                    "Simvastatin", 
                    "Evacetrapib and Simvastatin"
                ], 
                "description": "Administered orally.", 
                "intervention_name": "Simvastatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Atorvastatin", 
                    "Evacetrapib and Atorvastatin"
                ], 
                "description": "Administered orally.", 
                "intervention_name": "Atorvastatin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Simvastatin", 
                "Atorvastatin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "June 3, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China"
                }, 
                "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "6", 
        "official_title": "A Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Study of Evacetrapib With Selected Statins in Healthy Chinese Subjects", 
        "overall_contact": {
            "last_name": "There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or", 
            "phone": "1-317-615-4559"
        }, 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Pharmacokinetics:  Area Under the Concentration Curve (AUC) of Evacetrapib", 
                "safety_issue": "No", 
                "time_frame": "Part 1:  Predose on Day 1 or Day 14 through 168 hours postdose.  Part 2: Predose on Day 14 and Day 22 through 24 hours post dose."
            }, 
            {
                "measure": "Pharmacokinetics:  Maximum Concentration (Cmax) of Evacetrapib", 
                "safety_issue": "No", 
                "time_frame": "Part 1:  Predose on Day 1 or Day 14 through 168 hours postdose.  Part 2: Predose on Day 14 and Day 22 through 24 hours post dose."
            }, 
            {
                "measure": "Pharmacokinetics:  Time to Maximum Concentration (Tmax) of Evacetrapib", 
                "safety_issue": "No", 
                "time_frame": "Part 1:  Predose on Day 1 or Day 14 through 168 hours postdose.  Part 2: Predose on Day 14 and Day 22 through 24 hours post dose."
            }, 
            {
                "measure": "Pharmacokinetics:  Area Under the Concentration Curve (AUC) of Simvastatin and Atorvastatin", 
                "safety_issue": "No", 
                "time_frame": "Predose on Day 14 and 22 through 24 hours post dose"
            }, 
            {
                "measure": "Pharmacokinetics:  Maximum Concentration (Cmax) of  Simvastatin and Atorvastatin", 
                "safety_issue": "No", 
                "time_frame": "Predose on Day 14 and 22 through 24 hours post dose"
            }, 
            {
                "measure": "Pharmacokinetics:  Time to Maximum Concentration (Tmax) of Simvastatin and Atorvastatin", 
                "safety_issue": "No", 
                "time_frame": "Predose on Day 14 and 22 through 24 hours post dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02156492"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Change from Baseline in High Density Lipoprotein Cholesterol, Low Density Lipoprotein Cholesterol, and Triglycerides", 
            "safety_issue": "No", 
            "time_frame": "Baseline up to Day 14"
        }, 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}